We're #hiring a new Associate Director, Analytical CMC – Small Molecules in Charlottesville, Virginia. Apply today or share this post with your network.
About us
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/
- Website
-
https://www.rivuspharma.com/
External link for Rivus Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Rivus Pharmaceuticals
Updates
-
Our Phase 2a HuMAIN trial met the primary endpoint of weight reduction in patients w/ obesity-related heart failure. We're sharing detailed results highlighting our investigational therapy's potential to be the first disease-modifying #HFpEF treatment by enabling fat-specific weight loss while preserving muscle at this year's #HFSA Annual Scientific Meeting. Read more: https://bit.ly/4fArk2O
-
We're #hiring a new Senior Director / VP, Quality - GMP & GCP in San Francisco Bay Area. Apply today or share this post with your network.
-
Reductions in muscle mass pose a persistent challenge with current weight loss medicines. Our CEO Dr. Jayson Dallas and CSO Dr. Shaharyar Khan share how our approach, which increases energy expenditure by leveraging a process called mitochondrial uncoupling, could lead to fat-specific weight loss & improvements in cardiometabolic health. Read more at BioSpace: bit.ly/3zxWwzr
-
Our investigational Controlled Metabolic Accelerator increases metabolism and reduces body fat, which is pivotal to the development of #HFpEF. The rationale and design of our Phase 2a clinical trial in HFpEF are now published in European Society of Cardiology. Learn more: bit.ly/3VZWcBW.
-
-
Obesity and other metabolic diseases are major risk factors for #MASH. This Global Fatty Liver Day, we're joining the community in raising awareness about this progressive liver disease and the urgent need to expand treatment options for patients. Learn more about our approach to treating metabolic diseases: rivuspharma.com
-
-
Our CEO, Dr. Jayson Dallas, is sharing how we're shaking up the current treatment paradigm for metabolic diseases underserved by existing therapeutic options. Read more from FirstWord Pharma about our next-generation approach and its potential to help overcome the limitations of existing treatments by increasing metabolic rate: https://bit.ly/44LZRX1
-
🚨 Attention Job Seekers! 🚨 It has come to our attention that there are job scammers impersonating Rivus, and our employees. Please be vigilant and exercise caution when interacting with potential employers. Here are a few important reminders: - We always require an in person interview - We NEVER conduct interviews via Teams - We NEVER communicate via text message or other third-party apps - We always communicate using our company email address, we NEVER use gmail or other personalized email addresses - We NEVER provide a check to purchase home office equipment - Be wary of unsolicited job offers or requests for personal information Please be vigilant before you start communicating with any "recruiters" that contact you claiming they have a remote position that you are a fit for. Always check the company's website and LinkedIn page to verify that the job post is legitimate and the person you are communicating with actually works for Rivus.
-
We're #hiring a new Head, Quality - GCP/GMP/GLP in Charlottesville, Virginia. Apply today or share this post with your network.